OTCPK:REMI

Stock Analysis Report

Executive Summary

Remedent, Inc., through its subsidiaries, researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products.

Snowflake

Fundamentals

Excellent balance sheet and fair value.

Risks

  • Remedent is not covered by any analysts.

Share Price & News

How has Remedent's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

11.8%

REMI

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

-5.0%

REMI

9.9%

US Medical Equipment

0.7%

US Market

REMI underperformed the Medical Equipment industry which returned 9.9% over the past year.

REMI underperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

REMIIndustryMarket
7 Day11.8%1.1%-0.6%
30 Day5.6%1.3%2.9%
90 Day26.7%3.0%1.3%
1 Year-5.0%-5.0%10.8%9.9%2.9%0.7%
3 Year-9.5%-9.5%70.1%64.9%44.6%35.2%
5 Year-44.3%-44.3%138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Remedent's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Remedent undervalued based on future cash flows and its price relative to the stock market?

1.81x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Remedent's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Remedent's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Remedent is good value based on earnings compared to the US Medical Equipment industry average.

Remedent is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Remedent, we can't assess if its growth is good value.


Price Based on Value of Assets

Remedent is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Remedent expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

-26.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Remedent is high growth as no revenue estimate data is available.

Remedent's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.

Unable to compare Remedent's revenue growth to the United States of America market average as no estimate data is available.

Remedent's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.

Remedent's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Remedent will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Remedent performed over the past 5 years?

17.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Remedent's year on year earnings growth rate has been positive over the past 5 years.

Remedent has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Remedent has become profitable in the last year making it difficult to compare the US Medical Equipment industry average.


Return on Equity

Remedent made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).


Return on Assets

Remedent used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

It is difficult to establish if Remedent improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Remedent's financial position?


Financial Position Analysis

Remedent's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Remedent's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Remedent has no debt.

Remedent has no debt compared to 5 years ago when it was 88.9%.

Remedent has no debt, it does not need to be covered by operating cash flow.

Remedent has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Remedent has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Remedent's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Remedent's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Remedent's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Remedent has not reported any payouts.

Unable to verify if Remedent's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Remedent has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Remedent's salary, the management and board of directors tenure and is there insider trading?

13.4yrs

Average management tenure


CEO

Guy De Vreese (64yo)

10.8yrs

Tenure

US$38,852

Compensation

Mr. Guy De Vreese serves as Director at Glamsmile (Asia) Limited. Mr. De Vreese has been Chairman of Remedent, Inc. since April 1, 2002 and has been Chief Executive Officer of Remedent NV since December 10 ...


Management Age and Tenure

13.4yrs

Average Tenure

The average tenure for the Remedent management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

17.4yrs

Average Tenure

64yo

Average Age

The average tenure for the Remedent board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Guy De Vreese (64yo)

    Chairman & CEO

    • Tenure: 10.8yrs
    • Compensation: US$38.85k
  • Philippe Van Acker (54yo)

    CFO, Chief Accounting Officer & Director

    • Tenure: 10.8yrs
    • Compensation: US$182.28k
  • Mark Sernatinger

    Executive Officer of United States Office

    • Tenure: 13.4yrs
  • Scott Juhl

    Executive Officer of United States Office

    • Tenure: 13.4yrs
  • Stacey Ammons

    Executive Officer of United States Office

    • Tenure: 13.4yrs

Board Members

  • Guy De Vreese (64yo)

    Chairman & CEO

    • Tenure: 10.8yrs
    • Compensation: US$38.85k
  • Fred Kolsteeg (76yo)

    Director

    • Tenure: 17.4yrs
    • Compensation: US$117.49k
  • Philippe Van Acker (54yo)

    CFO, Chief Accounting Officer & Director

    • Tenure: 10.8yrs
    • Compensation: US$182.28k

Company Information

Remedent, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Remedent, Inc.
  • Ticker: REMI
  • Exchange: OTCPK
  • Founded: 1986
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$3.799m
  • Shares outstanding: 20.00m
  • Website: https://www.remedent.com

Number of Employees


Location

  • Remedent, Inc.
  • Zuiderlaan 1-3
  • Box 8
  • Ghent
  • East Flanders
  • 9000
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
REMIOTCPK (Pink Sheets LLC)YesCommon StockUSUSDOct 1998

Biography

Remedent, Inc., through its subsidiaries, researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products. It primarily provides professional veneers and teeth whiten ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 23:57
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.